Wilson Disease clinical trials at UC Davis
1 research study open to eligible people
Effectiveness and Safety of Experimental ALXN1840 Versus Standard of Care for Wilson Disease (copper buildup)
open to eligible people ages 12 years and up
The purpose of this study is to evaluate the efficacy of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in WD patients aged 12 and older.
Los Angeles, California and other locations